HCPCS Level II code J9198 denotes a 100 mg unit of gemcitabine hydrochloride (Infugem) administered as an antineoplastic injection. As a unit-based drug code, J9198 is central to billing chemotherapy infusions and impacts facility and professional service lines nationwide. Accurate use ensures proper capture of drug utilization and supports payment for outpatient cancer treatment.

Key payers evaluated include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for gemcitabine use, typical sites of service for billing, and the operational implications for infusion centers and oncology practices.

This publication provides benchmarks on code usage and reimbursement where available, summarizes relevant billing considerations for outpatient infusion services, and highlights common modifiers and service-line interactions that affect claims processing. Data not available in the input are noted explicitly. The content is intended for national audiences including billing staff, revenue cycle managers, and oncology practice administrators seeking a clear, practical reference for HCPCS Level II code J9198.